Literature DB >> 25922291

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.

Xiuning Le1, Jason A Freed1, Paul A VanderLaan2, Mark S Huberman1, Deepa Rangachari1, Susan E Jorge1, Antonio R Lucena-Araujo1, Susumu S Kobayashi1, Sohail Balasubramanian3, Jie He3, Yakov Chudnovsky3, Vincent A Miller3, Siraj M Ali3, Daniel B Costa4.   

Abstract

Entities:  

Keywords:  Anaplastic lymphoma kinase; C-ros oncogene 1; Hepatocyte growth factor receptor; Mutation; Next-generation sequencing

Mesh：

Substances：

Year:  2015        PMID： 25922291      PMCID： PMC4418215          DOI： 10.1016/j.cllc.2015.03.002

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  14 in total

Review 1.  Management and future directions in non-small cell lung cancer with known activating mutations.

Authors:  David E Gerber; Leena Gandhi; Daniel B Costa
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

2.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Authors:  Mark G Kris; Bruce E Johnson; Lynne D Berry; David J Kwiatkowski; A John Iafrate; Ignacio I Wistuba; Marileila Varella-Garcia; Wilbur A Franklin; Samuel L Aronson; Pei-Fang Su; Yu Shyr; D Ross Camidge; Lecia V Sequist; Bonnie S Glisson; Fadlo R Khuri; Edward B Garon; William Pao; Charles Rudin; Joan Schiller; Eric B Haura; Mark Socinski; Keisuke Shirai; Heidi Chen; Giuseppe Giaccone; Marc Ladanyi; Kelly Kugler; John D Minna; Paul A Bunn
Journal:  JAMA       Date:  2014-05-21       Impact factor: 56.272

3.  Cancer statistics, 2014.

Authors:  Rebecca Siegel; Jiemin Ma; Zhaohui Zou; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-07       Impact factor: 508.702

Review 4.  Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents.

Authors:  Sreenath V Sharma; Daniel A Haber; Jeff Settleman
Journal:  Nat Rev Cancer       Date:  2010-03-19       Impact factor: 60.716

5.  An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms.

Authors:  Helen Y Zou; Qiuhua Li; Joseph H Lee; Maria E Arango; Scott R McDonnell; Shinji Yamazaki; Tatiana B Koudriakova; Gordon Alton; Jingrong J Cui; Pei-Pei Kung; Mitchell D Nambu; Gerrit Los; Steven L Bender; Barbara Mroczkowski; James G Christensen
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

6.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Thorac Oncol       Date:  2013-07       Impact factor: 15.609

7.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.

Authors:  Gromoslaw A Smolen; Raffaella Sordella; Beth Muir; Gayatry Mohapatra; Anne Barmettler; Heidi Archibald; Woo J Kim; Ross A Okimoto; Daphne W Bell; Dennis C Sgroi; James G Christensen; Jeffrey Settleman; Daniel A Haber
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

8.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.

Authors:  Garrett M Frampton; Alex Fichtenholtz; Geoff A Otto; Kai Wang; Sean R Downing; Jie He; Michael Schnall-Levin; Jared White; Eric M Sanford; Peter An; James Sun; Frank Juhn; Kristina Brennan; Kiel Iwanik; Ashley Maillet; Jamie Buell; Emily White; Mandy Zhao; Sohail Balasubramanian; Selmira Terzic; Tina Richards; Vera Banning; Lazaro Garcia; Kristen Mahoney; Zac Zwirko; Amy Donahue; Himisha Beltran; Juan Miguel Mosquera; Mark A Rubin; Snjezana Dogan; Cyrus V Hedvat; Michael F Berger; Lajos Pusztai; Matthias Lechner; Chris Boshoff; Mirna Jarosz; Christine Vietz; Alex Parker; Vincent A Miller; Jeffrey S Ross; John Curran; Maureen T Cronin; Philip J Stephens; Doron Lipson; Roman Yelensky
Journal:  Nat Biotechnol       Date:  2013-10-20       Impact factor: 54.908

9.  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Authors:  James G Christensen; Helen Y Zou; Maria E Arango; Qiuhua Li; Joseph H Lee; Scott R McDonnell; Shinji Yamazaki; Gordon R Alton; Barbara Mroczkowski; Gerrit Los
Journal:  Mol Cancer Ther       Date:  2007-12       Impact factor: 6.261

Review 10.  Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.

Authors:  S E D C Jorge; S S Kobayashi; D B Costa
Journal:  Braz J Med Biol Res       Date:  2014-09-05       Impact factor: 2.590
View more
  5 in total

1.  MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation.

Authors:  Lisa Pei Chu; Debra Franck; Christine A Parachoniak; Jeffrey P Gregg; Michael G Moore; D Gregory Farwell; Shyam Rao; Andreas M Heilmann; Rachel L Erlich; Jeffrey S Ross; Vincent A Miller; Siraj Ali; Jonathan W Riess
Journal:  Oncologist       Date:  2019-08-07

2.  Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

Authors:  Susan E Jorge; Sol Schulman; Jason A Freed; Paul A VanderLaan; Deepa Rangachari; Susumu S Kobayashi; Mark S Huberman; Daniel B Costa
Journal:  Lung Cancer       Date:  2015-10-31       Impact factor: 5.705

3.  Comparison of Detection of Epidermal Growth Factor Receptor (EFGR) Gene Mutation in Peripheral Blood Plasma (Liquid Biopsy) with Cytological Specimens in Lung Adenocarcinoma Patients.

Authors:  Laksmi Wulandari; Gatot Soegiarto; Anna Febriani; Farah Fatmawati
Journal:  Indian J Surg Oncol       Date:  2020-02-05

4.  Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.

Authors:  Nai-Jung Chiang; Chiun Hsu; Jen-Shi Chen; Hsiao-Hui Tsou; Ying-Ying Shen; Yee Chao; Ming-Huang Chen; Ta-Sen Yeh; Yan-Shen Shan; Shiu-Feng Huang; Li-Tzong Chen
Journal:  Sci Rep       Date:  2016-05-03       Impact factor: 4.379

5.  Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant.

Authors:  Zheng Zhao; Zhangjun Song; Xuwei Wang; Haifeng Sun; Xiaomin Yang; Yong Yuan; Pan Yu
Journal:  Onco Targets Ther       Date:  2017-08-21       Impact factor: 4.147
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.